JPRN-UMIN000016148
Completed
Phase 2
Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot Study- - A pilot study of abatacept treatment in actu HBV patients with liver failure.
Hiroshima liver study group0 sites5 target enrollmentJanuary 7, 2015
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hiroshima liver study group
- Enrollment
- 5
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Autoimmune hepatitis 2\)History of hypersensitivity to abatacept 3\)Hepatic coma 4\)HBV carrier 5\)Serious infectious disease 6\)Judged by investigator not to be appropriate for inclusion in this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Analysis of Effectiveness and Safety of Abatacept in Japanese patients with Rheumatoid Arthritis.Rheumatoid arthritisJPRN-UMIN000005144Tokyo Medical and Dental university300
Completed
Phase 2
Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiencyCTLA4 insufficiency or LRBA deficiencyD84.9Immunodeficiency, unspecifiedDRKS00017736niversitätsklinikum Freiburg vertreten durch den Leitenden Ärztlichen Direktor und die Kaufmännische Direktorin20
Active, not recruiting
Phase 1
Examination of the drug abatacept (administered as syringe under the skin) in patients suffering from CTLA4 insufficiency or LRBA deficienca. Focus of inverstigation: side effects and effects on the clinical symptoms examined.Patients with a molecular confirmed diagnosis of CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) (haplo)-insufficiency or LRBA (Lipopolysaccharide-Responsive and Beige-like An¬chor) deficiencyMedDRA version: 20.1Level: PTClassification code 10021449Term: Immunodeficiency common variableSystem Organ Class: 10021428 - Immune system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2019-000972-40-DEniversitätsklinikum Freiburg20
Active, not recruiting
Phase 1
Aflibercept Efficacy in Patients Suffering Age-Related Damage of the Yellow Spot of the Light-sensitive Tissue Layer in the EyeEUCTR2014-002168-34-CZDoc. MUDr. Petr Kolár, PhD, Ocní klinika FN Brno45
Completed
Phase 2
Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosisD86.0Sarcoidosis of lungDRKS00011660niversitätsklinikum Freiburg30